INTRODUCTION
The endogenous catecholamines epinephrine and norepinephrine exert a variety of regulatory functions on human physiological processes. The initial sites of action of catecholamines seem to be at membrane adrenergic receptors. Based on the relative order of potencies of a series of adrenergic agonists, Ahlquist proposed that the effects of catecholamines were mediated by two distinct types of adrenergic receptors, termed aand ,3-adrenergic receptors (1) . /-Adrenergic responses (isoproterenol> epinephrine> norepinephrine) which are specifically antagonized by propranolol are typified by relaxation of smooth muscle and stimulation of cardiac contractility. a-Adrenergic responses (epinephrine> norepinephrine> isoproterenol) are potently antagonized by phentolamine and are typified by contraction of vascular and uterine smooth muscle.
Recent studies have shown that epinephrine and norepinephrine induce human platelet aggregation whereas isoproterenol does not (2) (3) (4) . This aggregation is blocked by the a-antagonist phentolamine (2) (3) (4) . Epinephrine and norepinephrine also cause a rapid decrease in prostaglandin E,-(PGE,)1-enhanced cyclic AMP (cAMP) levels in platelets and produce immediate decreases in platelet adenylate cyclase activity (5) (6) (7) (8) (9) (10) (11) . These responses are also blocked by the a-adrenergic blocker phentolamine. Thus, there is evidence that these adrenergic effects on platelets are mediated by a-adrenergic receptors.
The development of radioligand binding methods for the direct study of hormone and drug receptors over the past few years has facilitated the investigation of the properties and regulation of these receptors. Applied to human cell types, these methods provide an approach to the direct study of abnormalities of receptor function in various disease states (12, 13) .
Recently, Williams et al. described a ligand, [3H] dihydroergocryptine, which could be used to identify a-adrenergic receptors in uterine smooth muscle (14) . In the present studies we report the successful identification and characterization of a-adrenergic receptors in human platelets with [3H ]dihydroergocryptine. Binding of [3H]dihydroergocryptine to human platelet lysates has all the characteristics of specificity, stereoselectivity, saturability, and reversibility which would be expected of binding to a physiological a-adrenergic receptor. a-Receptor binding is also demonstrated in intact platelets. The specificity of the binding data is also correlated with an a-adrenergic response in the platelet lysates inhibition of PGE,-stimulated adenylate cyclase. Preparation ofplatelets and platelet lysates. 100-200 cm3 of blood were takei} from peripheral veins of healthy human volunteers. The first 5 cm3 of blood was discarded, and the remainder was collected with 3.2% sodium citrate as anticoagulant. The blood was centrifuged at 380 g for 10 min. The resulting platelet-rich plasma was centrifuged at 16,000 g for 10 min at 25°C. The resulting platelet pellet was resuspended in "buffer I" (Tris-HCl, 0.05 M, pH 7.35, NaCl 0.15 M, EDTA 0.02M) and then recentrifuged at 16,000 g for 10 min, resuspended in buffer I, and recentrifuged at 16,000 g for 10 min at 25°C. The washed platelets were resuspended in buffer I at a concentration of 1-2 x 1Q9 platelets/ml for use in binding assays or were resuspended in "lysing buffer" (Tris HCI 0.005M, pH 7.5, EDTA 0.005M) at 4°C for 1 min for preparation of platelet lysates. No significant contaminating leukocytes were found in stained preparations. This suspension was homogenized for 20 strokes with a motor-driven teflon-tipped pestle (controlled by a Powerstat rheostat (Fisher Scientific Co., Pittsburgh, Pa.) at a setting of 120 (-) pestle clearance 0.1-0.5 mm) and then centrifuged at 39,000 g for 10 min at 4°C. The final pellet was resuspended in "incubation buffer" (Tris-HCl 0.05 M, pH 7.5, EDTA 0.005 M) for use in the binding assay.
METHODS
Whole platelet and lysate preparations were examined by phase-contrast and interference-contrast microscopy at x 1000 magnification as well as by electron microscopy. The platelet preparations appeared intact. The lysate preparations show lysis of some platelets with areas of cell debris including scattered cytoplasmic granules and granule-free membrane fragments. Some apparently unlysed platelets were also seen, but these were markedly swollen.
[3H]Dihydroergocryptine binding assay.
[3H]Dihydroergocryptine (5 nM unless otherwise specified) and platelet lysates (2.0 mg/ml unless otherwise specified) or intact platelets (1-2 x 109/ml) were incubated at 25°C with shaking for 18 min in a total volume of 150 ,ul of incubation buffer for platelet lysates, or buffer I for intact platelets. In competition experiments, varying concentrations of agonists or antagonists were added to the incubation as indicated. Incubations were terminated by rapidly diluting the total volume with 2 ml of incubation buffer or buffer I at 250C followed by rapid filtration through Whatman GFC glass fiber filters (Whatman, Inc., Clifton, N. J.). Filters were rapidly washed with 20 ml of incubation buffer. After drying, filters were counted in a Tritontoluene scintillation mixture at an efficiency of 40-50%.
"Nonspecific" binding was defined as binding which was not displaced by a high concentration of 10 ,uM phentolamine, a potent a-adrenergic antagonist, or 1 mM epinephrine, an a-adrenergic agonist. In platelet lysates, 1 mM epinephrine and 10 ,uM phentolamine inhibited binding to the same extent, and higher concentration of phentolamine did not inhibit binding further. In intact platelets, 10 ,M phentolamine inhibited binding slightly, but consistently to a greater extent (-20%), than 1 mM epinephrine. Accordingly in studies with intact platelets we have used 1 mM epinephrine to determine nonspecific binding, assuming that all true a-adrenergic receptors should be accessible to epinephrine as well as phentolamine. "Specific" binding, defined as total binding minus nonspecific binding is shown in all figures and tables. Specific binding was generally 55-70% of the [3H]dihydroergocryptine bound in the platelet lysates and 30-40% in the intact platelets. In competition experiments with [3H]dihydroergocryptine present at -5 nM, specific binding was generally -110 fmol/mg protein in the platelet lysates.
To assess the integrity of the [3H]dihydroergocryptine the following experiment was performed. Binding incubations were performed in the usual manner. The membranes were then collected by centrifugation. Radioactivity from the supernate and that extracted from the pellet with ethanol was then chromatographed on thin layer plates as previously described in the solvent system chloroform:ethanol:acetic acid:9:5: 1 (14) . Both the bound and free [3H]dihydroergocryptine displayed R,s identical to native authentic material.
Protein was determined by the method of Lowry et. al. (15) . Adenylate cyclase assays. Adenylate cyclase assays of platelet lysates were performed by methods comparable to those previously described from this laboratory (16) . Assay volume was 50 ,ul containing 30 mM Tris-HCl (pH 7.4), 10 mM MgCl2, 0.1 mM cAMP, 1.5 mM ATP [a-32P]ATP (1-2 x 106 cpm), 5 mM phosphoenolpyruvate, pyruvate kinase (40 ,tg/ ml), and myokinase (20 gg/ml). Incubations were for 10 min at 37'C and were stopped by addition of 1 ml of a solution containing [3H]cAMP (15,000 cpm/ml), 100 ,ug ATP, and 50 ,ug cAMP.
[32P]cAMP that was formed was isolated by the method of Saloman et al. (17) . In separate experiments, it was demonstrated that the assay was linear with respect to protein and time over the time and concentration ranges used in these studies, and that the stopping solution in fact stopped the enzymatic reaction.
For the routine assay of a-adrenergic effects on platelet adenylate cyclase, the enzyme was stimulated by 10 ,uM PGE1. The ability of a-adrenergic agonists such as epinephrine to inhibit the PGE -stimulated enzyme was then measured. Inasmuch as has been noted previously (10) , platelet lysate adenylate cyclase is stimulated via a ,f-adrenergic receptor, all assays also contained 10 ,M (+)propranolol to block 83-adrenergic receptors. In general, PGE,-stimulated adenylate cyclase activity in the platelet lysates was 869+39 pmol cAMP generated/min per mg protein and was maximally reduced to 462 +24 pmol/min per mg by 1 mM epinephrine (n = 10 experiments).
Platelet aggregation. Platelet-rich plasma was prepared as described above. Platelet aggregation was initiated by addition of (-)epinephrine to a final concentration of 30 ,uM in a volume of 0.5 ml of stirred platelet rich plasma at 37°C. Aggregation was followed using a platelet aggregation profiler (PAP- (Fig. 4) . The a-adrenergic agonists had high affinity for the binding sites, with Kd values of 0.26 uM and 0.85 ,tM for (-)epinephrine and (-)norepinephrine, respectively (Table I) (Table I) . Several other ergot alkaloids such as ergotamine and dihydroergotamine were also potent in competing for binding (Table I ). (10, 11) . The pattern of inhibition by catecholamines appears to be that of an a-adrenergic response. Accordingly, we utilized epinephrine-stimulated inhibition of PGE1-stimulated adenylate cyclase 5.0r in the platelet lysates as a convenient biochemical assay of a-adrenergic effects which could be used for correlation with the [3H]dihydroergocryptine binding data.
a-Adrenergic catecholamine agonists inhibited enzyme activity with a relative potency order identical to that observed for inhibition of [3H]dihydroergocryptine binding and typical of an a-adrenergic receptor mediated process, i.e., (-)epinephrine > (-)norepinephrine > (-)isoproterenol (Fig. 7) . Inhibition of PGE,-stimulated adenylate cyclase activity by these catecholamines also displayed stereospecificity comparable to that observed in the binding studies (Fig. 7) .
Potent a-adrenergic antagonists such as phentola- The activity of the PGE,-stimulated adenylate cyclase which we observed in the platelet lysates was several-fold higher than that previously reported by several other laboratories (10, 19, 20) . This may be due to differences in membrane preparation (freeze-thaw or sonication vs. mechanical disruption) or assay conditions (higher ATP and PGE, concentrations in our experiments).
The characteristics of [3H]dihydroergocryptine binding to intact platelets appeared to be quite comparable to those observed in the platelet lysates. The number of receptors per platelet determined from the studies with lysates and intact platelets was also identical (220 per platelet). The ability of dihydroergoeryptine to inhibit epinephrine-induced platelet aggregation lends further credence to the contention that the sites labeled are in fact equivalent to the physiological a-adrenergic receptors.
The specificity of the [3H]dihydroergocryptine binding sites which we have identified appear to be identical to the previously demonstrated specificity of. (a) epinephrine-induced aggregation of platelets, which is blocked by phentolamine but not by ,8-antagonists (2-4); (b) epinephrine-induced reduction of PGE,-stimulated cAMP levels in intact platelets (5-9); and (c) epinephrine-induced inhibition of PGE,-stimulated adenylate cyclase in platelet lysates (10) .
All of these phenomena have typical characteristics of an a-adrenergic receptor-mediated process. Nonetheless, it should be noted that both our data and previous reports (10, 21) suggest that the platelet a-adrenergic receptors may differ in certain respects from other peripheral a-adrenergic receptors. For example, phenylephrine is a classical full agonist at peripheral aadrenergic receptors. However, it appeared to have only partial agonist activity in our study of adenylate cyclase and in previous reports was a partial agonist for reduction of cAMP levels in intact platelets (6) . Phenylephrine also appears to be devoid of agonist activity in aggregating platelets (21) .
The ability to study other hormone and drug receptors in circulating cells has provided a useful approach to the investigation of receptor abnormalities in human disease states (12, 22) . The ability to quantitate and characterize [3H]dihydroergocryptine binding sites in human platelets now extends this approach to the direct study of a-adrenergic receptors in normal and pathophysiologic states in man.
